tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Bill Maughan, 52 are a BUY (82.54%), 11 are a HOLD (17.46%).
Analyst Bill Maughan, currently employed at CANACCORD, carries an average stock price target met ratio of 39.47% that have a potential upside of 66.51% achieved within 158 days. Previously, Bill Maughan worked at TD COWEN.
Bill Maughan’s has documented 125 price targets and ratings displayed on 19 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on DNTH, Dianthus Therapeutics at 10-Mar-2026.
Analyst best performing recommendations are on CRSP (CRISPR THERAPEUTICS AG).
The best stock recommendation documented was for YMAB (Y MABS THERAPEUTICS) at 3/31/2023. The price target of $18 was fulfilled within 336 days with a profit of $12.99 (259.28%) receiving and performance score of 7.72.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 11-Dec-2021
$32
$16.87 (111.50%)
$30
2 months ago
(07-Aug-2026)
3/19 (15.79%)
$16.89 (111.78%)
716
Buy Since 05-Jan-2021
$21
$5.87 (38.80%)
$19
2 months 1 days ago
(06-Aug-2026)
3/11 (27.27%)
$5.53 (35.75%)
269
Buy Since 14-May-2024
$18
$5.06 (39.10%)
$25
11 months 2 days ago
(05-Nov-2025)
0/4 (0%)
$9.32 (107.37%)
Buy Since 18-Oct-2024
$21
$8.06 (62.29%)
$21
11 months 16 days ago
(21-Oct-2025)
0/2 (0%)
$9.61 (84.37%)
Buy Since 28-Jun-2024
$20
$7.06 (54.56%)
$21
11 months 16 days ago
(21-Oct-2025)
1/3 (33.33%)
$8.61 (75.59%)
325
What Year was the first public recommendation made by Bill Maughan?
